Form 8-K

0001171843-20-007574.txt : 20201104 0001171843-20-007574.hdr.sgml : 20201104 20201104160013 ACCESSION NUMBER: 0001171843-20-007574 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201104 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201104 DATE AS OF CHANGE: 20201104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTOKINETICS INC CENTRAL INDEX KEY: 0001061983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943291317 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50633 FILM NUMBER: 201286537 BUSINESS ADDRESS: STREET 1: 280 EAST GRAND AVENUE STREET 2: . CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 624-3000 MAIL ADDRESS: STREET 1: 280 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 f8k_110420.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2020

_______________________________

Cytokinetics, Incorporated

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	000-50633	94-3291317
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

280 East Grand Avenue

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 624-3000

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	CYTK	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 4, 2020, Cytokinetics, Incorporated (the "Company") announced its financial results for the third quarter ended September 30, 2020. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished under this Item 2.02 shall not be considered "filed" under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated November 4, 2020

Exhibit 104. Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Cytokinetics, Incorporated


Date: November 4, 2020	By:	/s/ Ching Jaw
		Ching Jaw
		Senior Vice President, Chief Financial Officer

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Cytokinetics Reports Third Quarter 2020 Financial Results

Topline Results From GALACTIC-HF Show Trial Met Primary Composite Endpoint
of Reduction in Cardiovascular Death or Heart Failure Events; Trial Did Not Meet Secondary Endpoint
of Reduction in Cardiovascular Death

Primary results from GALACTIC-HF to be presented as Late Breaking Clinical Trial Session at the
American Heart Association Scientific Sessions 2020 on November 13, 2020

Enrollment Completed in Cohort 1 of REDWOOD-HCM

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2020. Net loss for the third quarter was $3.2 million, or $0.05 per share, compared to net loss for the third quarter of 2019 of $29.6 million, or $0.50 per share. Cash, cash equivalents and investments totaled $451.2 million at September 30, 2020 and does not include $85 million expected upon the closing of RTW Investments’ purchase of Cytokinetics’ royalty rights on the future sales of mavacamten.

“We were pleased to recently announce positive topline results in GALACTIC-HF which demonstrated a reduction in the primary efficacy outcome endpoint with omecamtiv mecarbil.” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We look forward to the presentation of the primary results at the AHA Scientific Sessions, including pre-specified subgroup analyses which will elaborate on patients that had differential effects with our cardiac myosin activator. During the third quarter, we continued to make progress on our pipeline, highlighted by the advancement of CK-274 in REDWOOD-HCM and our advancing a second cardiac myosin inhibitor into clinical development. With a strong balance sheet, fortified by business development and financing deals completed in July, we are well positioned to continue funding the progression of our muscle-directed drug candidates in clinical trials.”

Recent Highlights

Cardiac Muscle Programs

omecamtiv mecarbil (cardiac myosin activator)

Completed conduct of closeout activities for GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil. Topline results from the trial were recently announced showing that treatment with omecamtiv mecarbil achieved the primary composite efficacy endpoint and demonstrated a statistically significant effect to reduce in cardiovascular (CV) death or heart failure events (heart failure hospitalization and other urgent treatment for heart failure), compared to placebo in patients treated with standard of care (HR: 0.92; 95% CI: 0.86, 0.99, p=0.0252). No reduction in the secondary endpoint of CV death was observed. Adverse events, including major ischemic cardiac events, were balanced between treatment arms.
Primary results from GALACTIC-HF will be presented at the American Heart Association (AHA) Scientific Sessions 2020, as part of a virtual Late Breaking Clinical Trial session on Friday, November 13, 2020 from 10:35-10.45 a.m. CDT.
Reviewing prespecified analyses and supplemental analyses of results of GALACTIC-HF in collaboration with Amgen. Discussions ongoing with Amgen on potential next steps.
Continued conduct of METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 trial of omecamtiv mecarbil. We expect enrollment to be completed in 1H 2021. METEORIC-HF is being conducted by Cytokinetics in collaboration with Amgen.

AMG 594 (cardiac troponin activator)

Convened advisory board of consultants to discuss potential indications to inform Phase 2 trial planning. Continued discussions of potential next steps in the development program with Amgen.

CK-3773274 (CK-274, cardiac myosin inhibitor)

Continued conduct of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial designed to determine the safety and tolerability of CK-274 in patients with obstructive hypertrophic cardiomyopathy (HCM). Recently completed enrollment of first cohort of patients in REDWOOD-HCM, summary data from which will inform progression to the second cohort of the trial, expected by the end of 2020.
Presented preclinical data at the American Association of Pharmaceutical Scientists (AAPS) 2020 PharmSci 360 showing that CK-274 demonstrated desirable pharmacokinetics in vivo, supporting the intended pharmacokinetic profile of once-daily oral dosing in humans and steady state plasma concentrations achieved within two weeks of initiation of dosing.

CK-271 (CK-271, second cardiac myosin inhibitor)

Initiated a Phase 1 study of CK-271, our second cardiac myosin inhibitor. We expect to complete the study by the end of 2020.

Skeletal Muscle Program

reldesemtiv (next-generation fast skeletal muscle troponin activator (FSTA))

Convened meetings with ALS community stakeholders to obtain feedback on endpoints and other matters relating to the design of a potential Phase 3 trial of reldesemtiv in patients with ALS.
Conducted readiness activities in preparation for the start of a potential Phase 3 clinical trial of reldesemtiv in patients with ALS.

Pre-Clinical Development and Ongoing Research

Continued pre-clinical development of CK-3762601 (CK-601), a next-generation FSTA. We expect to continue conduct of IND-enabling studies of CK-601 in 2020.
Published a manuscript on pre-clinical data in the Journal of Cachexia, Sarcopenia and Muscle, showing the fast skeletal muscle troponin activator CK-2066260 (CK-260) increases submaximal force in conditions with muscle weakness in vitro.
Continued research in collaboration with Astellas directed to the discovery of next-generation skeletal muscle activators.
Continued independent research activities directed to our other muscle biology research programs.

Corporate

Executed a series of transactions with affiliates of RTW Investments, LP, and Ji Xing Pharmaceuticals Limited related to CK-274 whereby Cytokinetics will receive a combination of committed capital, funding and sale proceeds of up to $250 million and is eligible to receive up to $200 million in milestone payments plus royalties on future sales of CK-274 in certain Asian countries
Raised $189 million in net proceeds, after deducting underwriting discounts and commissions, from an underwritten public offering in July of 8,385,417 shares of common stock including the underwriter’s exercise of their overallotment option.
Convened a virtual investor & analyst day to provide updates on the company’s advancing cardiovascular pipeline and strategies to build a commercial franchise.
Participated in the launch of Kainomyx, Inc., a new biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of parasitic diseases.
Provided $1 million grant and entered four-year partnership with the HCM Registry (HCMR), a global registry of patients with hypertrophic cardiomyopathy focused on improving predictive measures of risk for complications and identifying biomarkers associated with adverse clinical outcomes.
Renewed our partnership with Cure SMA to increase education, awareness, public policy and fundraising for spinal muscular atrophy (SMA).
Announced a call for proposals for the third annual Cytokinetics Communications Fellowship Grant program. The program provides $100,000 in grants to five selected patient advocacy organizations serving the ALS, heart failure, HCM, or SMA communities, and is intended to support increased capacity in communications, awareness building and community engagement.

Financials

Revenues for the three and nine months ended September 30, 2020 were $41.7 million and $49.1 million, respectively, compared to $6.1 million and $21.7 million for the corresponding periods in 2019. The increase in revenues for the three and nine month ended September 30, 2020 was primarily due to $36.5 million of license revenue recognized in the third quarter 2020 for the RTW transactions.

Research and development expenses for the three and nine months ended September 30, 2020 increased to $24.2 million and $67.7 million, respectively, compared to $20.2 million and $67.8 million for the same periods in 2019, respectively, due to increased spending on readiness for reldesemtiv and an increase in spending for our cardiac myosin inhibitor programs.

General and administrative expenses for the three and nine months ended September 30, 2020 increased to $12.3 million and $38.9 million from $9.8 million and $29.0 million in 2019 due primarily to an increase in personnel related costs including stock-based compensation and higher outside spending for commercial readiness.

Conference Call and Webcast Information

Members of Cytokinetics’ senior management team will review the company’s third quarter 2020 results via a webcast and conference call today at 4:30 PM Eastern Time. The webcast can be accessed through the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or +1 (706) 679-3078 (international) and typing in the passcode 3979672.

An archived replay of the webcast will be available via Cytokinetics’ website until November 18, 2020. The replay will also be available via telephone by dialing (855) 859-2056 (United States and Canada) or +1 (404) 537-3406 (international) and typing in the passcode 3979672 from November 4, 2020 at 7:30 PM Eastern Time until November 18, 2020.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is collaborating with Amgen Inc. (Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of an international clinical trials program in patients with heart failure including GALACTIC-HF, of which topline results were recently reported, and METEORIC-HF, which is ongoing. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator (FSTA) for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is considering potential advancement of reldesemtiv to Phase 3. Cytokinetics is collaborating with Astellas Pharma Inc. (Astellas) to research, develop and commercialize other novel mechanism skeletal sarcomere activators (excluding FSTAs). Licenses held by Amgen and Astellas are subject to specified co-development and co-commercialization rights of Cytokinetics. Cytokinetics is also developing CK-274, a novel cardiac myosin inhibitor that company scientists discovered independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics has granted Ji Xing Pharmaceuticals Limited an exclusive license to develop and commercialize CK-274 in China and Taiwan, in accordance with Cytokinetics’ planned global registration programs. Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development and commercial readiness activities, including the initiation, conduct, design, enrollment, progress, continuation, completion, timing and results of clinical trials, including the completion of enrollment in METEORIC-HF and the availability of results from the first cohort of patients in REDWOOD-HCM, Cytokinetics’ ability to ensure commercial readiness and develop co-promotion plans in collaboration with Amgen; the significance and utility of pre-clinical study and clinical trial results, including the results of GALACTIC-HF in respect of omecamtiv mecarbil; planned interactions with regulatory authorities in connection to any of Cytokinetics’ drug candidates and the outcomes of such interactions, including discussions in preparation for a potential Phase 3 clinical trial and registration program for reldesemtiv in patients with ALS and the prospects for FDA and other regulatory agency approval of omecamtiv mecarbil; the ability of Cytokinetics to fulfill applicable contractual conditions and receive a combination of committed capital, funding and sale proceeds of up to $250 million or any portion of such amount from affiliates of RTW Investments, LP, and/or Ji Xing Pharmaceuticals Limited; the ability of Cytokinetics to earn milestone payments and royalties from Ji Xing Pharmaceuticals Limited in connection to the development and commercialization of CK-274 in certain Asian countries; the expected timing of events and milestones; and the properties and potential benefits of Cytokinetics’ drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to Cytokinetics’ need for additional funding and such additional funding may not be available on acceptable terms, if at all; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials; Amgen’s decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil and AMG 594; Cytokinetics may incur unanticipated research and development and other costs; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757

Cytokinetics, Incorporated
Condensed Consolidated Balance Sheets
(in thousands)


	September 30, 2020			December 31, 2019
	(unaudited)
ASSETS
Current assets:
Cash and short term investments	$	410,264		$	225,112
Other current assets		8,148			8,640
Total current assets		418,412			233,752
Long-term investments		40,958			42,650
Property and equipment, net		7,667			4,530
Operating lease right-of-use assets and other assets		7,075			8,882
Total assets	$	474,112		$	289,814
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued liabilities	$	21,224		$	20,283
Short-term lease liability		3,943			4,616
Other current liabilities		2,406			1,124
Total current liabilities		27,573			26,023
Term loan, net		45,920			45,052
Convertible notes, net		88,102			84,205
Liability related to the sale of future royalties, net		160,395			143,276
Long-term lease and other non-current liabilities		2,517			2,195
Total liabilities		324,507			300,751
Commitments and contingencies
Stockholders’ equity (deficit):
Common stock		70			59
Additional paid-in capital		1,096,953			853,341
Accumulated other comprehensive income		958			679
Accumulated deficit		(948,376	)		(865,016	)
Total stockholders’ equity (deficit)		149,605			(10,937	)
Total liabilities and stockholders’ equity (deficit)	$	474,112		$	289,814

Cytokinetics, Incorporated
Condensed Consolidated Statements of Operations
(in thousands except per share data)
(unaudited)

	Three Months Ended						Nine Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019
Revenues:
Research and development revenues	$	5,187		$	6,055		$	12,605		$	21,656
License revenues		36,501			—			36,501			—
Total revenues		41,688			6,055			49,106			21,656
Operating expenses:
Research and development		24,202			20,229			67,730			67,791
General and administrative		12,302			9,753			38,912			29,026
Total operating expenses		36,504			29,982			106,642			96,817
Operating income (loss)		5,184			(23,927	)		(57,536	)		(75,161	)
Interest expense		(3,976	)		(1,345	)		(11,945	)		(3,892	)
Non-cash interest expense on liability related to the sale of future royalties		(5,461	)		(5,321	)		(17,062	)		(15,204	)
Interest and other income		1,078			1,020			3,183			3,205
Net loss	$	(3,175	)	$	(29,573	)	$	(83,360	)	$	(91,052	)
Net loss per share — basic and diluted	$	(0.05	)	$	(0.50	)	$	(1.34	)	$	(1.60	)
Weighted-average number of shares used in computing net loss per share — basic and diluted		68,279			58,640			62,406			57,050

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Class A [Member] Preferred Class A [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_110420_htm.xml IDEA: XBRL DOCUMENT 0001061983 2020-11-04 2020-11-04 iso4217:USD shares iso4217:USD shares 0001061983 false 8-K 2020-11-04 Cytokinetics, Incorporated DE 000-50633 94-3291317 280 East Grand Avenue South San Francisco CA 94080 650 624-3000 false false false false Common Stock, par value $0.001 CYTK NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 04, 2020
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 04, 2020
Entity File Number	000-50633
Entity Registrant Name	Cytokinetics, Incorporated
Entity Central Index Key	0001061983
Entity Tax Identification Number	94-3291317
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	280 East Grand Avenue
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	624-3000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	CYTK
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_110420.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_110420.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k_110420.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_110420.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_110420.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 15 0001171843-20-007574-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-20-007574-xbrl.zip M4$L#!!0 ( : 9%$5XQ.<]B( !0Q 0 + 97AH7SDY,2YH=&WM7>EV MV\BQ?H+[#GT=)Y'.!2EP)RV/S]%(LJV,;#D2)TY^@D!31 P"�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